BVNA — an approved system in Europe — treats vertebrogenic pain. This form of chronic low back pain is associated with bony lesions on vertebral endplates. The minimally invasive, implant-free procedure can take place at both inpatient and outpatient bases. It uses targeted radiofrequency energy to block the nervus basivertebralis from transmitting pain signals to the brain. This improves function and provides sustainable relief.
Relievant Medsystems — which Boston Scientific acquired for $850 million last year — also develops a BVNA system. Relievant’s minimally invasive, FDA-cleared, same-day, outpatient procedure also treats chronic vertebrogenic low back pain.
Dr. Andreas Kurth, a user of radiofrequency technology to treat spinal metastasis, said access to this type of therapy could enhance the treatment spectrum in the field of interventional chronic pain management, according to a news release.
The Ladenburg, Germany-based startup’s next plans include investing in infrastructure to enable broad market access and meet growing demand. Eric Schaber, New4med shareholder and strategy consultant said the launch begins a rollout of many new spinal surgery approaches.
New4med aims to make its high-growth therapeutic option available to a broad population of people.
“By offering BVNA to physicians, we are providing access to this unique treatment for people with vertebrogenic pain in Europe for the first time,” said Daniel Seifert, shareholder and designated CEO of New4med.
